Chetan Padmakar Darne

This inventor holds 14 USPTO granted patents and 5 published patent applications and 10 EPO patents. Top assignees: Bristol-Myers Squibb Compnay, Rigel Pharmaceuticals, Incorporated, Bayer Intellectual Property Gmbh. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chetan Padmakar Darne. Retrieved from https://idiyas.com/inventor/chetan-padmakar-darne

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 5)

% Patents Active = 100.0

EPO Patents = 10 (Patent Applications = 10)

Average Co-Inventor Count = 10.2

ph-index = 2

Forward Citations = 18(Granted Patents)

Location History:

Wallingford, CT (US) (2014)
Orange, CT (US) (2013 - 2019)
Ewing, NJ (US) (2020 - 2023)

Company Filing History:

11 out of 3,745

Bristol-Myers Squibb Compnay

patents

2 out of 492

Rigel Pharmaceuticals, Incorporated

patents

1 out of 721

Bayer Intellectual Property Gmbh

patents

4. 1 out of 41

Bristol Meyers Squibb Company

patents

5. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12454531 - Substituted piperazine derivatives useful as T cell activators (2025-10-28),

2. 11713316 - Substituted naphthyridinone compounds useful as T cell activators (2023-08-01),

3. 11584747 - Substituted pyridopyrimidinonyl compounds useful as T cell activators (2023-02-21),

4. 10961239 - TGF beta receptor antagonists (2021-03-30),

5. 10954238 - Substituted naphthyridinone compounds useful as T cell activators (2021-03-23),

6. 10669272 - Substituted naphthyridinone compounds useful as T cell activators (2020-06-02),

7. 10287295 - TGF-β inhibitors (2019-05-14),

8. 9884868 - TGF-beta inhibitors (2018-02-06),

9. 9598423 - Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors (2017-03-21),

10. 9556179 - Substituted imidazoles as casein kinase 1 D/E inhibitors (2017-01-31),

11. 9475817 - Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors (2016-10-25),

12. 9273058 - Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors (2016-03-01),

13. 8916553 - Sulfonamide compounds useful as CYP17 inhibitors (2014-12-23),

14. 8501755 - Tetrahydropyridothienopyrimidine compounds and methods of use thereof (2013-08-06),

Title: Chetan Padmakar Darne: Innovator in T Cell Activation

Introduction

Chetan Padmakar Darne is a prominent inventor based in Orange, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that act as T cell activators. With a total of 14 patents to his name, Darne's work is pivotal in addressing viral infections and proliferative disorders, such as cancer.

Latest Patents

Among his latest patents, Darne has developed substituted piperazine derivatives that are useful as T cell activators. These compounds are designed to inhibit the activity of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ). Additionally, he has disclosed methods for using these compounds in pharmaceutical compositions aimed at treating various medical conditions. Another notable patent involves substituted naphthyridinone compounds, which also serve as T cell activators and share similar applications in the treatment of viral infections and cancer.

Career Highlights

Chetan Darne has worked with leading pharmaceutical companies, including Bristol-Myers Squibb Company and Rigel Pharmaceuticals, Incorporated. His experience in these organizations has allowed him to collaborate on groundbreaking research and development projects that have advanced the field of immunotherapy.

Collaborations

Throughout his career, Darne has collaborated with notable professionals, including Upender Velaparthi and Jayakumar Sankara Warrier. These partnerships have contributed to the successful development of innovative therapeutic solutions.

Conclusion

Chetan Padmakar Darne is a distinguished inventor whose work in T cell activation has the potential to transform treatment options for serious health conditions. His extensive patent portfolio and collaborations with leading companies highlight his significant impact on the pharmaceutical industry.

Profile summary based on public USPTO records.